Chosen Diagnostics Inc receives NICHD award to develop diagnostic test for necrotizing enterocolitis in preemie babies
Chosen Diagnostics Inc announces the receipt of a $300K Phase I Small Business Technology Transfer award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health. The project “Noninvasive biomarkers for gastrointestinal disease in preterm infants” will focus on the development of a diagnostic biomarker for necrotizing enterocolitis.
Necrotizing enterocolitis (NEC) affects 6,000 premature American infants each year. For infants with NEC, more than a third die. Following advanced stages of NEC, survivors end up with disabilities and a diminished quality of life. The disease lacks accurate diagnosis in the neonatal intensive care units and also lacks disease-modifying treatments. A biomarker that improves diagnosis of the disease will lower mortality and life-long health complications.
Prior support of the research commercialization was generously provided by the National Science Foundation I-Corps programs, VentureWell ASPIRE, LSU Leveraging Innovation for Technology Transfer Fund, the Louisiana Board of Regents Industrial Ties Research Program, the Louisiana Business and Technology Center at LSU, Jefferson Economic Development Commission, and the New Orleans Bioinnovation Center.
Since 2017, we have been focused on delivering better outcomes for the most urgent and complex challenges for the most fragile patient population. CDI is an award-winning woman-owned small business that combines scientific expertise with leading-edge technologies in biomarker development.